NCT02071134 Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
| NCT ID | NCT02071134 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Scientific Corporation |
| Condition | Parkinson's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2014-03-04 |
| Primary Completion | 2038-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2014-03-04 with a primary completion date of 2038-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Eligibility Criteria
Key Inclusion Criteria: * Meets criteria established in locally applicable Vercise System Direction for Use * At least 18 years old Key Exclusion Criteria: * Meets any contraindication in the Vercise System locally applicable Directions for Use Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
Contact & Investigator
Natalie Bloom Lyons
STUDY DIRECTOR
Boston Scientific Neuromodulation Corporation
Frequently Asked Questions
Who can join the NCT02071134 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02071134 currently recruiting?
Yes, NCT02071134 is actively recruiting participants. Contact the research team at BSNClinicalTrials@bsci.com for enrollment information.
Where is the NCT02071134 trial being conducted?
This trial is being conducted at Aliso Viejo, United States, Los Angeles, United States, Aurora, United States, Grand Junction, United States and 11 additional locations.
Who is sponsoring the NCT02071134 clinical trial?
NCT02071134 is sponsored by Boston Scientific Corporation. The principal investigator is Natalie Bloom Lyons at Boston Scientific Neuromodulation Corporation. The trial plans to enroll 1,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.